bearish
Burning Rock Biotech (BNR US): Muted Near-Term Outlook on Resurgence of COVID-19 in China
203 Views07 Nov 2021 20:11
SUMMARY
- Burning Rock Biotech (BNR US) is China’s leading NGS-based therapy selection testing company for late-stage cancer patients. Thus far, the company has completed more than 300,000 tissue and liquid-based tests.
- The company is in a structural transition towards in-hospital business model, which is negatively impacting the blended ASP and profitability. Due to upcoming new product launch in next year and ongoing clinical studies, opex is now accounting for more than 230% of revenue, which is expected to continue.
- Amid the recent spread of delta variant in China, this insight has analyzed near-term growth prospect of Burning Rock ahead of its Q3 results announcement on November 16.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Burning Rock Biotech (BNR US): Despite Q2 Results Missing Consensus Management Reiterated Guidance01 Sep 2022
- Burning Rock Biotech (BNR US) 1Q22: Double-Digit Revenue Growth; China Re-Opening to Boost Recovery02 Jun 2022
- Burning Rock Biotech (BNR US): Attractive Growth Story Outshined by Surging COVID Cases in China31 Mar 2022
- Burning Rock Biotech (BNR US): Muted Near-Term Outlook on Resurgence of COVID-19 in China07 Nov 2021
- Burning Rock (燃石医学) IPO Trading: Hot Deal, Small Float12 Jun 2020
- Burning Rock IPO Valuation: Warm and Pleasant10 Jun 2020
- Burning Rock Biotech IPO: Valuation Insights09 Jun 2020
x